Evidence map›Paper›PMID 39334897›Full record

ArticleBiomolecules2024

An Enhanced Retroviral Vector for Efficient Genetic Manipulation and Selection in Mammalian Cells.

Jana Triller, Iryna Prots, Hans-Martin Jäck, Jürgen Wittmann

Abstract read
In one paragraph

Article in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jana TrillerDivision of Molecular Immunology, Department of Internal Medicine III, Nikolaus-Fiebiger-Center of Molecular Medicine (NFZ), Friedrich-Alexander-Universität Erlangen-Nürnberg, Glückstraße 6, D-91054 Erlangen, Germany.
Iryna ProtsDepartment of Operative Dentistry and Periodontology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Glückstraße 11, D-91054 Erlangen, Germany.
Hans-Martin JäckDivision of Molecular Immunology, Department of Internal Medicine III, Nikolaus-Fiebiger-Center of Molecular Medicine (NFZ), Friedrich-Alexander-Universität Erlangen-Nürnberg, Glückstraße 6, D-91054 Erlangen, Germany.ORCID 0000-0002-6332-8463
Jürgen WittmannDivision of Molecular Immunology, Department of Internal Medicine III, Nikolaus-Fiebiger-Center of Molecular Medicine (NFZ), Friedrich-Alexander-Universität Erlangen-Nürnberg, Glückstraße 6, D-91054 Erlangen, Germany.ORCID 0000-0003-0404-8186

Funding

Deutsche Forschungsgemeinschaft 505539112/KFO5024Deutsche Forschungsgemeinschaft Doctoral Training Group GRK2599Deutsche Forschungsgemeinschaft TRR130ELAN Fond of the University Hospital of Erlangen P117Fritz Thyssen Foundation 10.19.2.024MNJohannes and Frieda Marohn-Foundation n.a.Kastner-Stiftung n.a.
6 · The paper itself

Abstract

Introducing genetic material into hard-to-transfect mammalian cell lines and primary cells is often best achieved through retroviral infection. An ideal retroviral vector should offer a compact, selectable, and screenable marker while maximizing transgene delivery capacity. However, a previously published retroviral vector featuring an EGFP/Puromycin fusion protein failed to meet these criteria in our experiments. We encountered issues such as low infection efficiency, weak EGFP fluorescence, and selection against infected cells. To address these shortcomings, we developed a novel retroviral vector based on the Moloney murine leukemia virus. This vector includes a compact bifunctional EGFP and Puromycin resistance cassette connected by a 2A peptide. Our extensively tested vector demonstrated superior EGFP expression, efficient Puromycin selection, and no growth penalty in infected cells compared with the earlier design. These benefits were consistent across multiple mammalian cell types, underscoring the versatility of our vector. In summary, our enhanced retroviral vector offers a robust solution for efficient infection, reliable detection, and effective selection in mammalian cells. Its improved performance and compact design make it an ideal choice for a wide range of applications involving precise genetic manipulation and characterization in cell-based studies.

Indexed as

Genetic VectorsGreen Fluorescent ProteinsMoloney murine leukemia virusRetroviridaeAnimalsHEK293 CellsHumansMicePuromycinTransgenesenhanced green fluorescent proteinGreen Fluorescent ProteinsPuromycinB cellsEGFPFACSfusion proteininfectionlinkerPuromycinretrovirusT2A

Identifiers

PMID39334897
PMCPMC11430422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.